$ACOG News

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20

Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism

Alpha Cognition Inc. Common Stock Q2 2026 Earnings Call Summary

Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Alpha Cognition Q2 2026 Earnings Call Transcript

Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M Estimate

Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release